If you’ve been treated for depression and still don’t feel better, you’re not alone — and you’re not out of options. For a significant number of people with major depressive disorder, the first medications tried don’t bring full relief. When this happens, it doesn’t mean treatment has failed. It means a different approach is needed.
This is what treatment-resistant depression is — and why there is real reason for hope.
What Defines Treatment-Resistant Depression?
Treatment-resistant depression (TRD) is most commonly defined as depression that has not improved despite adequate trials of at least two different antidepressant medications, taken at the right dose, for the right duration (typically at least 8 weeks each), with good adherence to the treatment plan.
This is the definition used by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and it’s the standard most clinicians and researchers use today.
Some important context:
– TRD is common. It is estimated that approximately 30% of people with major depressive disorder meet this definition — roughly one in three.
– Only about one-third of patients respond fully to their first antidepressant. The landmark STARD study — one of the largest real-world depression treatment trials ever conducted — found that even after four carefully optimized treatment steps, cumulative remission reached only about 67%. With each successive step, the likelihood of remission decreased.
– TRD is not rare or unusual. It is a recognized clinical reality that requires a different treatment strategy — not a sign that something is wrong with the patient.
Before a diagnosis of TRD is made, providers should confirm that the original depression diagnosis is accurate, rule out conditions that can mimic or complicate depression (such as bipolar disorder, thyroid dysfunction, or substance use), and verify that medications were taken consistently. Nonadherence to antidepressants is estimated at 46%, making this an essential step.
Why Don’t First Medications Always Work?
This is one of the most important questions in psychiatry — and the honest answer is that depression is far more biologically complex than any single medication can address.
Most first-line antidepressants — SSRIs and SNRIs — work primarily by increasing the availability of serotonin and norepinephrine in the brain. For many people, this is enough.
But for others, the underlying biology of their depression involves pathways that these medications simply don’t reach.
Here’s what research has uncovered about why some people don’t respond:
Depression is not one disease. It is a syndrome — a collection of symptoms that can arise from many different biological causes. Two people with identical symptoms may have very different underlying brain chemistry, which means the same medication may work for one and not the other.
Inflammation plays a major role. People with TRD consistently show higher levels of inflammatory markers — including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a), and C-reactive protein (CRP) — compared to both healthy individuals and people whose depression responds to treatment. This chronic neuroinflammation can impair the very brain circuits that antidepressants are trying to repair. Standard antidepressants do not directly target inflammation, which may explain why they fall short for some patients.
The glutamate system matters. Traditional antidepressants target the monoamine system (serotonin, norepinephrine, dopamine), but research has shown that the glutamate system — the brain’s primary excitatory neurotransmitter network — is also disrupted in depression, particularly in TRD. This is why newer treatments like ketamine and esketamine, which target glutamate receptors, can work when traditional medications don’t.
Genetics influence treatment response. Genetic variations affect how the body metabolizes medications, how neurotransmitter receptors function, and how the brain responds to stress. Research has identified genetic factors related to neuroplasticity, cognition, neuroticism, and sleep that predict who is more likely to develop treatment resistance. Depression that is more severe, recurrent, and early-onset tends to have a stronger genetic component — and a higher likelihood of treatment resistance.
Other complicating factors include comorbid anxiety disorders, personality disorders, chronic pain, cardiovascular disease, and early-life adversity — all of which can reduce the likelihood of responding to standard antidepressants.
The bottom line: treatment resistance is not a personal failing. It reflects the biological complexity of depression and the limitations of medications that target only one piece of a much larger puzzle.
Hope for Advanced Treatments
The good news is that the science of treating TRD has advanced dramatically. There are now several evidence-based options that work through entirely different mechanisms than traditional antidepressants — and they are helping people who had lost hope.
Transcranial Magnetic Stimulation (TMS)
TMS is a non-invasive brain stimulation treatment that uses focused magnetic pulses to stimulate specific areas of the brain involved in mood regulation — particularly the left dorsolateral prefrontal cortex, which is known to be underactive in depression.
How it works: A TMS device is placed against the scalp and delivers magnetic pulses that stimulate nerve cells in targeted brain regions. No anesthesia is required, and patients remain awake throughout the procedure. Standard treatment involves daily sessions (typically 30–45 minutes) over 4–6 weeks, though newer protocols like theta-burst stimulation can deliver treatment in as little as 3 minutes per session.
What the evidence shows:
– TMS is FDA-approved for treatment-resistant depression.
– A large health technology assessment found that TMS produced an absolute risk reduction of approximately 23% compared to sham treatment, with a number needed to treat (NNT) of 4 — meaning that for every four patients treated, one achieves a response who would not have with sham treatment.
– Meta-analyses of TMS specifically in patients who have failed two or more antidepressants show that patients are over twice as likely to achieve both response and remission compared to sham treatment.
– Theta-burst stimulation (TBS), a newer and faster form of TMS, has been shown to be non-inferior to standard TMS, making treatment more accessible.
– Side effects are generally mild — most commonly headache and scalp discomfort — and there is no systemic medication involved.
TMS is a strong option for people who want an effective treatment without the side effects of additional medications.
Spravato (Intranasal Esketamine)
Spravato is the brand name for intranasal esketamine, a nasal spray that was FDA-approved in 2019 for treatment-resistant depression in adults. It works through an entirely different mechanism than traditional antidepressants — targeting the glutamate system rather than serotonin or norepinephrine.
How it works: Esketamine is administered as a nasal spray in a certified healthcare setting. Patients are monitored for at least two hours after each dose due to potential side effects like dissociation and sedation. Treatment typically begins with twice-weekly sessions during the first month, then transitions to weekly or every-other-week maintenance.
What the evidence shows:
– In clinical trials, esketamine significantly reduced depression scores compared to placebo, with effects observed as early as 24 hours after the first dose — a speed of action that traditional antidepressants cannot match.
– A recent randomized trial demonstrated that esketamine is also effective as monotherapy (without an oral antidepressant), with effect sizes of 0.48 for the 56 mg dose and 0.63 for the 84 mg dose — expanding options for patients who cannot tolerate oral antidepressants.
– Meta-analyses confirm significantly higher remission rates with esketamine compared to placebo, with the 84 mg and flexible-dose regimens showing the strongest effects.
– Real-world studies have confirmed these findings, showing that moderate-to-severe baseline symptoms were reduced to the mild range after 4 weeks, with effects sustained over 16 weeks of treatment.
– Year-long studies show that continued esketamine treatment leads to lower relapse rates with no considerable long-term side effects.
– The most common side effects are nausea, dissociation, dizziness, and headache — most of which are transient and resolve within hours of treatment.
Spravato represents a genuine breakthrough for people with TRD, offering rapid relief through a novel mechanism of action.
IV Ketamine
Intravenous (IV) ketamine is the treatment that sparked the revolution in TRD research. While not FDA-approved specifically for depression, it is increasingly used off-label based on a robust and growing body of evidence. Like esketamine, it works through the glutamate system, but it is administered as an intravenous infusion rather than a nasal spray.
How it works: A subanesthetic dose of ketamine (typically 0.5 mg/kg) is administered intravenously over 40 minutes in a clinical setting. Treatment protocols typically involve a series of six infusions over two to three weeks, sometimes followed by maintenance infusions.
What the evidence shows:
– A 2026 meta-analysis of 26 randomized controlled trials (1,166 patients) found that a single ketamine infusion produced significant reductions in depressive symptoms within 4 hours, with effects persisting through 24 hours, 3 days, and 1 week. Repeated infusions showed sustained benefit at the end of treatment.
– In the ELEKT-D trial — one of the largest ketamine trials to date — 38% of patients with TRD achieved remission with ketamine, and ketamine was found to be non-inferior to electroconvulsive therapy (ECT), which has long been considered the gold standard for severe TRD.
– Repeated infusions show cumulative antidepressant effects, with response rates reaching approximately 59% after a series of six infusions. Maintenance infusions (once weekly) can sustain these gains.
– Ketamine also rapidly reduces suicidal ideation — an effect that is critically important in the acute management of severe depression.
– Side effects include transient dissociation, dizziness, and blood pressure elevations, which typically resolve within hours. Serious adverse events are rare.
IV ketamine offers one of the fastest-acting antidepressant effects available and is particularly valuable for patients in acute crisis or those who have not responded to other interventions.
You Are Not Out of Options
If you’ve tried multiple medications and still feel stuck, it’s important to know this: treatment-resistant does not mean untreatable. It means the right treatment hasn’t been found yet.
The treatments described here — TMS, Spravato, and IV ketamine — represent real advances in our understanding of how depression works in the brain and how to treat it when standard approaches fall short. They work through different biological pathways, they have strong evidence behind them, and they are helping people every day.
The most important step is to talk to your provider. Ask about these options. Ask for a referral to a psychiatrist who specializes in treatment-resistant depression. And above all, don’t give up — because the science hasn’t given up on you.
Looking Ahead
While many individuals find relief through therapy, medication, lifestyle changes, or a combination of treatments, these approaches do not work for everyone. When depression symptoms persist despite appropriate care, it can be frustrating, discouraging, and difficult to know what steps to take next.
In our next blog post, we’ll explore advanced depression therapies that may offer hope when traditional treatments have not been effective. We’ll discuss innovative options such as Transcranial Magnetic Stimulation (TMS), Spravato® (esketamine), and IV ketamine therapy, along with how these treatments work and who may be good candidates. Understanding the full range of available treatments can help individuals recognize that there are often additional paths forward, even after previous approaches have fallen short.
